keyword
MENU ▼
Read by QxMD icon Read
search

Desvenlafaxine

keyword
https://www.readbyqxmd.com/read/29677603/the-comparative-evidence-basis-for-the-efficacy-of-second-generation-antidepressants-in-the-treatment-of-depression-in-the-us-a-bayesian-meta-analysis-of-food-and-drug-administration-reviews
#1
Rei Monden, Annelieke M Roest, Don van Ravenzwaaij, Eric-Jan Wagenmakers, Richard Morey, Klaas J Wardenaar, Peter de Jonge
BACKGROUND: Studies have shown similar efficacy of different antidepressants in the treatment of depression. METHOD: Data of phase-2 and -3 clinical-trials for 16 antidepressants (levomilnacipran, desvenlafaxine, duloxetine, venlafaxine, paroxetine, escitalopram, vortioxetine, mirtazapine, venlafaxine XR, sertraline, fluoxetine, citalopram, paroxetine CR, nefazodone, bupropion, vilazodone), approved by the FDA for the treatment of depression between 1987 and 2016, were extracted from the FDA reviews that were used to evaluate efficacy prior to marketing approval, which are less liable to reporting biases...
April 6, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29620924/desvenlafaxine-versus-placebo-in-a-fluoxetine-referenced-study-of-children-and-adolescents-with-major-depressive-disorder-design-definitions-and-ongoing-challenges-for-child-and-adolescent-psychopharmacology-research
#2
Jeffrey R Strawn, Paul E Croarkin
No abstract text is available yet for this article.
April 5, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29588433/sexual-dysfunction-in-patients-with-antidepressant-treated-anxiety-or-depressive-disorders-a-pragmatic-multivariable-longitudinal-study
#3
S Preeti, S D Jayaram, A Chittaranjan
OBJECTIVE: To investigate early evolution, tolerability, and predictors of antidepressant-emergent sexual dysfunction in patients with anxiety or depressive disorder. METHODS: Patients with anxiety or depressive disorders who were prescribed antidepressant monotherapy (mirtazapine, sertraline, desvenlafaxine, escitalopram, or fluoxetine) at the discretion of the treating clinician were recruited from July 2012 to June 2014 from a hospital outpatient service. All were free of psychotropic medication for least 1 month...
March 2018: East Asian Archives of Psychiatry: Official Journal of the Hong Kong College of Psychiatrists
https://www.readbyqxmd.com/read/29497300/drug-drug-interactions-involving-antidepressants-focus-on-desvenlafaxine
#4
REVIEW
Yvette Low, Sajita Setia, Graca Lima
Psychiatric and physical conditions often coexist, and there is robust evidence that associates the frequency of depression with single and multiple physical conditions. More than half of patients with depression may have at least one chronic physical condition. Therefore, antidepressants are often used in cotherapy with other medications for the management of both psychiatric and chronic physical illnesses. The risk of drug-drug interactions (DDIs) is augmented by complex polypharmacy regimens and extended periods of treatment required, of which possible outcomes range from tolerability issues to lack of efficacy and serious adverse events...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29489029/serotonin-and-noradrenaline-reuptake-inhibitors-snris-for-fibromyalgia
#5
REVIEW
Patrick Welsch, Nurcan Üçeyler, Petra Klose, Brian Walitt, Winfried Häuser
BACKGROUND: Fibromyalgia is a clinically defined chronic condition of unknown etiology characterized by chronic widespread pain that often co-exists with sleep disturbances, cognitive dysfunction and fatigue. People with fibromyalgia often report high disability levels and poor quality of life. Drug therapy, for example, with serotonin and noradrenaline reuptake inhibitors (SNRIs), focuses on reducing key symptoms and improving quality of life. This review updates and extends the 2013 version of this systematic review...
February 28, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29403141/desvenlafaxine-overdose-induced-toxic-cardiomyopathy-and-acute-left-ventricular-failure-a-case-report
#6
Sandeep Kumar Goyal, Chanchal Gera, Mamta Singla, Nitin Kumar
No abstract text is available yet for this article.
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29344746/desvenlafaxine-induced-interstitial-pneumonitis-a-case-report
#7
Arjan Flora, Daniel Pipoly
A 52-year-old man developed interstitial pneumonitis during treatment with desvenlafaxine for major depressive disorder. The man received desvenlafaxine at 50 mg for symptoms of depression 4 years earlier. Six months after a dose increase to 100 mg, he developed bronchitic symptoms with mild, persistent dyspnea. Investigations revealed a restrictive pattern on pulmonary function testing, bilateral upper lobe reticular opacities with traction bronchiectasis on radiology imaging, and end-stage interstitial fibrosis with honeycomb changes consistent with chronic hypersensitivity pneumonitis on open lung biopsy...
January 17, 2018: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/29344340/assessment-and-management-of-sexual-dysfunction-in-the-context-of-depression
#8
REVIEW
Pratap R Chokka, Jeffrey R Hankey
Sexual dysfunction (SD) is pervasive and underreported, and its effects on quality of life are underestimated. Due in part to its bidirectional relationship with depression, SD can be difficult to diagnose; it is also a common side effect of many antidepressants, leading to treatment noncompliance. While physicians often count on patients to spontaneously report SD, treatment is optimized when the clinician instead performs a thorough assessment of sexual functioning before and during drug therapy using a standardized questionnaire such as the Arizona Sexual Experiences Scale (ASEX)...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29327136/signal-detection-for-recently-approved-products-adapting-and-evaluating-self-controlled-case-series-method-using-a-us-claims-and-uk-electronic-medical-records-database
#9
Xiaofeng Zhou, Ian J Douglas, Rongjun Shen, Andrew Bate
INTRODUCTION: The Self-Controlled Case Series (SCCS) method has been widely used for hypothesis testing, but there is limited evidence of its performance for safety signal detection. OBJECTIVE: The objective of this study was to evaluate SCCS for signal detection on recently approved products. METHODS: A retrospective study covered the period after three recently marketed drugs were launched through to 31 December 2010 using The Health Improvement Network, a UK primary care database, and Optum, a US claims database...
January 11, 2018: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29228473/population-pharmacokinetics-of-desvenlafaxine-pharmacokinetics-in-korean-versus-us-populations
#10
Alice I Nichols, Sam Liao, Richat Abbas
Desvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis. Data from a single- and multiple-dose study of desvenlafaxine (50, 100, and 200 mg) in 30 healthy Korean subjects were added to a population PK model previously developed using sparse PK samples from patients with major depressive disorder, including 140 Korean patients, combined with rich PK data from healthy volunteers. The structural PK model was an open 1-compartment linear disposition model with parallel first-order and 0-order inputs...
December 11, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29189044/desvenlafaxine-versus-placebo-in-a-fluoxetine-referenced-study-of-children-and-adolescents-with-major-depressive-disorder
#11
Karen L Weihs, William Murphy, Richat Abbas, Deborah Chiles, Richard D England, Sara Ramaker, Dalia B Wajsbrot
OBJECTIVES: To evaluate the short-term efficacy and safety of desvenlafaxine (25-50 mg/d) compared with placebo in children and adolescents with major depressive disorder (MDD). METHODS: Outpatient children (7-11 years) and adolescents (12-17 years) who met DSM-IV-TR criteria for MDD and had screening and baseline Children's Depression Rating Scale-Revised (CDRS-R) total scores >40 were randomly assigned to 8-week treatment with placebo, desvenlafaxine (25, 35, or 50 mg/d based on baseline weight), or fluoxetine (20 mg/d)...
February 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29185786/desvenlafaxine-versus-placebo-in-the-treatment-of-children-and-adolescents-with-major-depressive-disorder
#12
Sarah Atkinson, Shannon Lubaczewski, Sara Ramaker, Richard D England, Dalia B Wajsbrot, Richat Abbas, Robert L Findling
OBJECTIVE: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). METHODS: Outpatient children (7-11 years) and adolescents (12-17 years) who met DSM-IV-TR criteria for MDD and had screening and baseline Children's Depression Rating Scale-Revised (CDRS-R) total scores >40 were randomly assigned to 8 weeks of treatment with placebo, low exposure desvenlafaxine (20, 30, or 35 mg/day based on baseline weight), or higher exposure desvenlafaxine (25, 35, or 50 mg/day based on baseline weight)...
February 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29170178/false-positive-phencyclidine-pcp-on-urine-drug-screen-attributed-to-desvenlafaxine-pristiq-use
#13
T Michael Farley, Emily N Anderson, Jade N Feller
We report a likely false-positive phencyclidine (PCP) result detected with a urine drug screen (UDS) (Medtox, St Paul, Minnesota, USA) in the setting of therapeutic desvenlafaxine (Pristiq) use. Desvenlafaxine (O-desmethylvenlafaxine) is the active metabolite of venlafaxine (Effexor). Prior reports have confirmed venlafaxine use resulting in a false-positive for PCP on a UDS. However, there has been a paucity of reporting of commercially available desvenlafaxine formulations (Pristiq, Khedezla) resulting in false-positives for PCP on a UDS...
November 23, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29154157/efficacy-of-antidepressants-on-measures-of-workplace-functioning-in-major-depressive-disorder-a-systematic-review
#14
REVIEW
Yena Lee, Joshua D Rosenblat, JungGoo Lee, Nicole E Carmona, Mehala Subramaniapillai, Margarita Shekotikhina, Rodrigo B Mansur, Elisa Brietzke, Jae-Hon Lee, Roger C Ho, Samantha J Yim, Roger S McIntyre
INTRODUCTION: Work-related disability and productivity loss in Major Depressive Disorder (MDD) are critical determinants of patient quality of life and contribute significantly to the human and economic costs of MDD. Notwithstanding the return to work and pre-morbid levels of functioning as a critical therapeutic objective among individuals with MDD, it is unclear whether antidepressant treatment significantly and reliably improves measures of workplace functioning. Herein, we investigate to what extent antidepressant treatment improves workplace functioning among adults with MDD...
February 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29140227/categorical-improvement-in-functional-impairment-in-depressed-patients-treated-with-desvenlafaxine
#15
Claudio N Soares, Min Zhang, Matthieu Boucher
OBJECTIVE: This post-hoc pooled analysis evaluated categorical change in functional impairment in patients with major depressive disorder (MDD) treated with desvenlafaxine versus placebo and examined whether early improvement in functioning predicted functional outcomes at study endpoint. METHODS: Data were pooled from eight randomized, double-blind, placebo-controlled studies of desvenlafaxine for the treatment of MDD, including adults who were randomly assigned to receive desvenlafaxine 50 or 100 mg/d or placebo (N=3,384)...
November 15, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29134498/vasoplegic-shock-treated-with-methylene-blue-complicated-by-severe-serotonin-syndrome
#16
Betty S Chan, Therese Becker, Angela L Chiew, Ahmed M Abdalla, Tom A Robertson, Xin Liu, Michael S Roberts, Nicholas A Buckley
INTRODUCTION: Management of severe vasoplegic shock in overdose can be very challenging. We describe a case of severe refractory vasodilatory shock in poisoning where methylene blue (MB) was used with success. However, the patient subsequently developed severe Serotonin Syndrome (SS) as a result of an interaction between serotonergic drugs and MB. CASE REPORT: A 15-year-old male developed severe vasoplegic shock 1.5 hours after overdosing on several different medications including quetiapine slow release, quetiapine immediate release, desvenlafaxine slow release, venlafaxine, amlodipine, ramipril, fluoxetine, promethazine and lithium...
November 13, 2017: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
https://www.readbyqxmd.com/read/29061415/antidepressant-related-jitteriness-syndrome-in-anxiety-and-depressive-disorders-incidence-and-risk-factors
#17
Preeti Sinha, Disha Jayaram Shetty, Laxminarayana K Bairy, Chittaranjan Andrade
INTRODUCTION: Jitteriness syndrome (JS) is a poorly understood but important adverse effect of antidepressant drugs. This study examined the incidence and pattern of antidepressant-related JS and its predictors. METHODS: 209 patients diagnosed with any anxiety or depressive disorder and started on mirtazapine, sertraline, desvenlafaxine, escitalopram or fluoxetine were assessed at baseline, after 2 weeks, and after 6 weeks with psychopathology rating scales and for predefined categories of JS...
October 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28951668/development-and-evaluation-of%C3%A2-desvenlafaxine-loaded-plga-chitosan-nanoparticles-for-brain-delivery
#18
Gui-Feng Tong, Nan Qin, Li-Wei Sun
Depression is a debilitating psychiatric condition that remains the second most common cause of disability worldwide. Currently, depression affects more than 4 per cent of the world's population. Most of the drugs intended for clinical management of depression augment the availability of neurotransmitters at the synapse by inhibiting their neuronal reuptake. However, the therapeutic efficacy of antidepressants is often compromised as they are unable to reach brain by the conventional routes of administration...
September 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/28929323/what-type-and-dose-of-antidepressants-are-cancer-and-non-cancer-inpatients-being-prescribed-a-retrospective-case-control-study-at-an-australian-tertiary-hospital
#19
Saira Sanjida, Kelly Mulvogue, Joanne Shaw, Jeremy Couper, David Kissane, Sallie-Anne Pearson, Melanie A Price, Monika Janda
PURPOSE: Cancer patients are often prescribed antidepressants, but little data is available about whether the type and dose are similar to prescriptions to patients with other chronic diseases. This study compared the prescription practices of antidepressants to cancer and non-cancer inpatients at a major Australian tertiary hospital and assessed side effects and potential drug-drug interactions. METHODS: Inpatients diagnosed with cancer within the past 12 months and prescribed antidepressants were age and gender matched to inpatients with other chronic disease conditions...
February 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28888484/prediction-of-human-efficacious-antidepressant-doses-using-the-mouse-forced-swim-test
#20
Eunice Yuen, Steven Swanson, Jeffrey M Witkin
The forced swim test (FST) is a commonly used preclinical animal behavioural model for prediction of antidepressant activity in humans. While the FST may qualitatively predict efficacy, less is known about the quantitative translation of FST data to human efficacious doses. Assessing quantitative translation allows better predictions of human efficacious doses and a higher chance of success in the drug development process. Dose-response and time-course FST experiments were carried out on mice using four marketed antidepressants (citalopram, desipramine, bupropion, desvenlafaxine) in addition to ketamine, all with varying mechanisms of action...
October 2017: Pharmacology, Biochemistry, and Behavior
keyword
keyword
48023
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"